Identification of the molecular mechanisms of non-response to treatments, relapses and remission in autoimmune, inflammatory, and allergic conditions
Project factsheets
Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).
Displaying 191 projects/programmes
Antibiotic distribution and recovery in tissue
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk
Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes
Alzheimer's disease apolipoprotein pathology for treatment elucidation and development
Accelerated development of vaccine benefit-risk collaboration in Europe
Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy
Autism Innovative Medicine Studies – 2 – Trials
Antimicrobial Resistance Accelerator
Amyloid imaging to prevent Alzheimer’s disease
Applied public-private research enabling osteoarthritis clinical headway
Accelerating research & development for advanced therapies
Big Data for Better Outcomes
Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare
Biomarker enterprise to attack DKD
Big data @ heart
Central repository for digital pathology
Biomarkers in atopic dermatitis and psoriasis
Biomarkers for Enhanced Vaccine Immunosafety
Be The Cure
conect4children - Collaborative network for European clinical trials for children
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
Cardiomyopathy in type 2 diabetes mellitus
Corona accelerated R&D in Europe
Chemical manufacturing methods for the 21st century pharmaceutical industries
Clinical impact through AI-assisted MS care
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Combatting Bacterial Resistance in Europe
Collaboration for prevention and treatment of MDR bacterial infections
Collaboration on the optimisation of macromolecular pharmaceutical access to cellular targets
Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
COVID-19 infections - remote early detection
Drug Disease Model Resources
A minituarized disposable molecular diagnostics platform for combatting coronavirus infections
Diabetes research on patient stratification
Big data for better outcomes, policy innovation and healthcare system transformation
Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics
Development of Robust and Innovative Vaccine Effectiveness
Driving re-investment in R&D and responsible antibiotic use
European Bank for induced pluripotent Stem Cells
EBiSC2 – A sustainable European bank for induced pluripotent stem cells
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment
Ebola and other filoviral haemorrhagic fevers
Ebola virus: modern approaches for developing bedside rapid diagnostics
Manufacturing and development for rapid access Ebola vaccine
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II
Bringing a prophylactic Ebola vaccine to licensure
Ensuring the future of EUPATI beyond 2020
European Health Data and Evidence Network
Electronic Health Records Systems for Clinical Research
European Lead Factory
European Medical Information Framework
European Medicines Research Training Network
European Gram-negative Antibacterial Engine
European prevention of Alzheimer’s dementia consortium
European Platform for Neurodegenerative Diseases
European Quality In Preclinical Data
European regimen accelerator for tuberculosis
European screening centre; unique library for attractive biology
Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities
Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management
Delivering European Translational Information & Knowledge Management Services
European Autism Interventions - a Multicentre Study for Developing New Medications
EU patient-centric clinical trial platform
European programme in Pharmacovigilance and Pharmacoepidemiology
EUbOPEN: Enabling and unlocking biology in the OPEN
European Patients' Academy on Therapeutic Innovation
Understanding chronic pain and improving its treatment
Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem
FAIRplus
Ultra-fast molecular filovirus diagnostics
Standardization and development of assays for assessment of influenza vaccines correlates of protection
Incorporating real-life clinical data into drug development
The GetReal Initiative
Novel Gram-negative antibiotic now
Gravitate–Health: Empowering and equipping Europeans with health information for active personal health management and adherence to treatment
Guiding multi-modal therapies against MRD by liquid biopsies
H2O Health outcomes observatory
Healthcare alliance for resourceful medicines offensive against neoplasms in hematology
Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS
Health initiatives in psoriasis and psoriatic arthritis consortium European states
Hypoglycaemia - REdefining SOLutions for better liVEs
Inhaled antibiotics in bronchiectasis and cystic fibrosis
Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production
Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases
Integration of heterogeneous data and evidence towards regulatory and HTA acceptance
Investigating mechanisms and models predictive of accessibility of therapeutics (IM2PACT) into the brain
Imaging and advanced guidance for workflow optimization in interventional oncology
Improving the care of patients suffering from acute or chronic pain
Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes
Integrated immunoprofiling of large adaptive cancer patients cohorts
Specific imaging of immune cell dynamics using novel tracer strategies
Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
Development of Impentri, an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)
Inhibiting misfolded protein propagation in neurodegenerative diseases
Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies
Innovations to accelerate vaccine development and manufacture
Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes.
Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA
Intelligent Assessment of Pharmaceuticals in the Environment
ITCC pediatric preclinical POC platform
Kinetics for Drug Discovery
Evaluation of a production ready portable, point-of-need platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection
Liver Investigation: Testing Marker Utility in Steatohepatitis
Intermediate AMD: development of novel clinical endpoints for clinical trials in patients with a regulatory and patient access intention
Modern approaches for developing antivirals against SARS-CoV 2
Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis
Machine learning ledger orchestration for drug discovery
Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury
Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
Mobile Filovirus Nucleic Acid Test
Models of patient engagement for Alzheimer’s disease
New Drugs for Bad Bugs
New clinical endpoints in primary Sjögren’s syndrome: an interventional trial based on stratifying patients
Neurotoxicity de-risking in preclinical drug discovery
Efficiently networking European neurodegeneration research
Novel methods leading to new medications in depression and schizophrenia
Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments
Methods for systematic next generation oncology biomarker development
The Open Pharmacological Concepts Triple Store
Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Oral biopharmaceutics tools
Patients active in research and dialogues for an improved generation of medicines: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes
Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
PERtussIS COrrelates of Protection Europe
Building a reproducible single-cell experimental workflow to capture tumour drug persistence
Pan Ebola vaccine innovative approach
Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
PharmaLedger
Pharmaceutical Medicine Training Programme
Prostate cancer diagnosis and treatment enhancement through the power of big data in Europe
Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases
New models for preclinical evaluation of drug efficacy in common solid tumours
Model-based preclinical development of anti-tuberculosis drug combinations
Patient Preferences in benefit risk assessments during the drug life cycle
Prioritisation and risk evaluation of medicines in the environment
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD
Psychiatric ratings using intermediate stratified markers 2
Physical Activity as a Crucial Patient Reported Outcome in COPD
Precision medicine platform in neurodegenerative disease
Preparing for RSV immunisation and surveillance in Europe
Pharmacoepidemiological research on outcomes of therapeutics by a European consortium
Proton versus photon therapy for esophageal cancer - a trimodality strategy
Quantative imaging in cancer:connecting cellular process with therapy
Remote assessment of disease and relapse – Alzheimer’s disease
Remote Assessment of Disease and Relapse in Central Nervous System Disorders
Robust automation and point of care identification of COVID
Development of rapid point-of-care test platforms for infectious diseases
Real world handling of protein drugs - exploration, evaluation and education
Respiratory syncytial virus consortium in Europe
Research empowerment on solute carriers
Add medical genetic solutions to RESOLUTE (REsolution)
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
Real world outcomes across the AD spectrum for better care: multi-modal data access platform
Rheuma Tolerance for Cure
Safer and Faster Evidence-based Translation
European Modular Education and Training Programme in Safety Sciences for Medicines
Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
Stratification of obese phenotypes to optimize future obesity therapy
Sarcopenia and physical frailty in older people: multi‐component treatment strategies
Stem cells for biological assays of novel drugs and predictive toxicology
Saracatinib trial to prevent FOP
Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools
Accelerating development and improving access to CAR and TCR-engineered T cell therapy
Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
Molecular basis of the bacterial cell wall permeability
Translational quantitative systems toxicology to improve the understanding of the safety of medicines
Center of excellence – remote decentralised clinical trials
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments
Imaging biomarkers (IBs) for safer drugs: validation of translational imaging methods in drug safety assessment
Unbiased biomarkers for the prediction of respiratory disease outcomes
Unrestricted leveraging of targets for research advancement and drug discovery
Academia and industry united innovation and treatment for tuberculosis
Vaccine lot to vaccine lot comparison by consistency testing
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
Viral haemorrhagic fever: modern approaches for developing bedside rapid diagnostics
Vaccines and infectious diseases in the ageing population
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
Recognising Adverse Drug Reactions
WEB-RADR 2
Zoonotic anticipation and preparedness initiative
